CY1114842T1 - Κιναζολινικα παραγωγα - Google Patents

Κιναζολινικα παραγωγα

Info

Publication number
CY1114842T1
CY1114842T1 CY20131101057T CY131101057T CY1114842T1 CY 1114842 T1 CY1114842 T1 CY 1114842T1 CY 20131101057 T CY20131101057 T CY 20131101057T CY 131101057 T CY131101057 T CY 131101057T CY 1114842 T1 CY1114842 T1 CY 1114842T1
Authority
CY
Cyprus
Prior art keywords
kinazolin
products
compounds
treating cancer
cancer
Prior art date
Application number
CY20131101057T
Other languages
English (en)
Inventor
Weihan Zhang
Wei-Guo Su
Haibin Yang
Yumin Cui
Yongxin Ren
Xiaoqiang Yan
Original Assignee
Hutchison Medipharma Enterprises Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchison Medipharma Enterprises Limited filed Critical Hutchison Medipharma Enterprises Limited
Publication of CY1114842T1 publication Critical patent/CY1114842T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Μέθοδος για τη θεραπεία του καρκίνου με μία από αυτές τις ενώσεις.
CY20131101057T 2008-06-30 2013-11-26 Κιναζολινικα παραγωγα CY1114842T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/164,610 US8426430B2 (en) 2008-06-30 2008-06-30 Quinazoline derivatives
EP09774296.9A EP2318378B1 (en) 2008-06-30 2009-06-30 Quinazoline derivatives

Publications (1)

Publication Number Publication Date
CY1114842T1 true CY1114842T1 (el) 2016-12-14

Family

ID=41466556

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131101057T CY1114842T1 (el) 2008-06-30 2013-11-26 Κιναζολινικα παραγωγα

Country Status (22)

Country Link
US (2) US8426430B2 (el)
EP (1) EP2318378B1 (el)
JP (1) JP5602729B2 (el)
KR (1) KR101664503B1 (el)
AU (1) AU2009267136B2 (el)
BR (1) BRPI0908635B8 (el)
CA (1) CA2726040C (el)
CY (1) CY1114842T1 (el)
DK (1) DK2318378T3 (el)
ES (1) ES2442946T3 (el)
HR (1) HRP20140066T8 (el)
MX (1) MX2010012692A (el)
MY (1) MY150493A (el)
NZ (1) NZ589191A (el)
PH (1) PH12010502934A1 (el)
PL (1) PL2318378T3 (el)
PT (1) PT2318378E (el)
RU (1) RU2505534C2 (el)
SG (2) SG10201604677RA (el)
SI (1) SI2318378T1 (el)
TW (1) TWI407962B (el)
WO (1) WO2010002845A2 (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110094574A1 (en) 2009-10-27 2011-04-28 Calisolar Inc. Polarization Resistant Solar Cell Design Using SiCN
CN102311438A (zh) * 2010-06-30 2012-01-11 和记黄埔医药（上海）有限公司 喹唑啉化合物
WO2012000182A1 (en) * 2010-06-30 2012-01-05 Hutchison Medipharma Limited Quinazoline compounds
CN102906086B (zh) * 2010-06-30 2014-02-12 和记黄埔医药（上海）有限公司 喹唑啉化合物
TWI466888B (zh) * 2011-05-25 2015-01-01 Hutchison Medipharma Ltd 喹唑啉化合物
AR092289A1 (es) 2011-11-14 2015-04-15 Sunshine Lake Pharma Co Ltd Derivados de aminoquinazolina y sus sales y metodos de uso
CN102659692B (zh) 2012-05-04 2014-04-09 郑州泰基鸿诺药物科技有限公司 双联厄洛替尼及其制备方法
CN102702115A (zh) * 2012-05-24 2012-10-03 盛世泰科生物医药技术(苏州)有限公司 一种4-氯-7-氟-6-硝基喹唑啉的合成方法
CN102775315A (zh) * 2012-07-31 2012-11-14 上海应用技术学院 一种间氨基苯乙炔的制备方法
CN103275018B (zh) * 2013-04-26 2016-03-02 浙江工业大学 4-[3-氯-4-取代苯胺基]-6-取代甲酰氨基喹唑啉类化合物及制备和应用
CN108863951A (zh) * 2017-05-16 2018-11-23 和记黄埔医药（上海）有限公司 化合物的盐及其晶型
WO2020007219A1 (zh) * 2018-07-02 2020-01-09 南京明德新药研发有限公司 一种egfr抑制剂的晶型及其制备方法
CN110903253B (zh) * 2019-12-13 2020-12-25 西安交通大学医学院第一附属医院 一种喹唑啉酮类化合物及其制备方法和应用
CN117940411A (zh) * 2021-08-30 2024-04-26 浙江海正药业股份有限公司 喹唑啉类衍生物、或其制备方法和用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5430148A (en) * 1992-03-31 1995-07-04 Agouron Pharmaceuticals, Inc. Antiproliferative quinazolines
JP2994165B2 (ja) * 1992-06-26 1999-12-27 ゼネカ・リミテッド キナゾリン誘導体、その製造法および該キナゾリン誘導体を含有する抗癌作用を得るための医薬調剤
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9508565D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
ES2174250T5 (es) * 1996-04-12 2010-04-21 Warner-Lambert Company Llc Inhibidores irreversibles de tirosina quinasas.
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6235741B1 (en) 1997-05-30 2001-05-22 Merck & Co., Inc. Angiogenesis inhibitors
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
IL135622A0 (en) 1997-11-06 2001-05-20 American Cyanamid Co Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps
US7074800B1 (en) 1999-02-10 2006-07-11 Astrazeneca Ab Quinazoline derivatives as angiogenesis inhibitors
US6943161B2 (en) 1999-12-28 2005-09-13 Pharmacopela Drug Discovery, Inc. Pyrimidine and triazine kinase inhibitors
CZ20023951A3 (cs) 2000-06-22 2004-01-14 Pfizer Products Inc. Substituované bicyklické deriváty pro léčení abnormálního buničného růstu
DE10063435A1 (de) 2000-12-20 2002-07-04 Boehringer Ingelheim Pharma Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
CA2439143A1 (en) * 2001-02-26 2002-09-06 Mcgill University Combi-molecules having signal transduction inhibitory properties and dna damaging properties
JPWO2002070477A1 (ja) 2001-03-01 2004-07-02 小野薬品工業株式会社 ２−メチルインドール−４−酢酸、その製造方法およびその合成中間体の製造方法
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
DE10204462A1 (de) 2002-02-05 2003-08-07 Boehringer Ingelheim Pharma Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
CN1678321A (zh) 2002-07-29 2005-10-05 里格尔药品股份有限公司 用2,4－嘧啶二胺化合物治疗或者预防自体免疫性疾病的方法
JO2785B1 (en) 2003-05-27 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinazoline derivatives
US7442698B2 (en) 2003-07-24 2008-10-28 Amgen Inc. Substituted heterocyclic compounds and methods of use
GB0321710D0 (en) 2003-09-16 2003-10-15 Novartis Ag Organic compounds
AU2004309166B2 (en) 2003-12-23 2008-02-21 Pfizer Inc. Novel quinoline derivatives
WO2006071079A1 (en) 2004-12-29 2006-07-06 Hanmi Pharm. Co., Ltd. Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof
KR100735639B1 (ko) * 2004-12-29 2007-07-04 한미약품 주식회사 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
WO2006138304A2 (en) 2005-06-14 2006-12-28 Taigen Biotechnology Pyrimidine compounds
US20090182140A1 (en) * 2005-12-02 2009-07-16 Mitsubishi Tanabe Pharma Corporation Alicyclic Heterocyclic Compound
DK2068880T3 (da) 2006-09-18 2012-07-23 Boehringer Ingelheim Int Fremgangsmåde til behandling af cancer, der huser EGFR-mutationer

Also Published As

Publication number Publication date
AU2009267136B2 (en) 2013-10-10
EP2318378B1 (en) 2013-10-23
DK2318378T3 (da) 2013-11-18
JP5602729B2 (ja) 2014-10-08
PT2318378E (pt) 2014-01-03
US20130217661A1 (en) 2013-08-22
WO2010002845A2 (en) 2010-01-07
PL2318378T3 (pl) 2014-05-30
RU2011103207A (ru) 2012-08-10
CA2726040C (en) 2014-08-12
SI2318378T1 (sl) 2014-03-31
BRPI0908635B8 (pt) 2021-05-25
NZ589191A (en) 2013-03-28
HRP20140066T8 (en) 2014-03-28
WO2010002845A3 (en) 2010-04-01
EP2318378A4 (en) 2012-05-09
RU2505534C2 (ru) 2014-01-27
US20100009958A1 (en) 2010-01-14
BRPI0908635A8 (pt) 2018-12-18
SG167561A1 (el) 2011-01-28
BRPI0908635A2 (pt) 2015-10-13
KR20110025741A (ko) 2011-03-11
HRP20140066T1 (hr) 2014-02-28
AU2009267136A1 (en) 2010-01-07
US8426430B2 (en) 2013-04-23
TWI407962B (zh) 2013-09-11
SG10201604677RA (en) 2016-07-28
BRPI0908635B1 (pt) 2020-09-01
ES2442946T3 (es) 2014-02-14
MY150493A (en) 2014-01-30
EP2318378A2 (en) 2011-05-11
KR101664503B1 (ko) 2016-10-12
TW201002329A (en) 2010-01-16
CA2726040A1 (en) 2010-01-07
MX2010012692A (es) 2010-12-20
JP2011526913A (ja) 2011-10-20
PH12010502934A1 (en) 2010-01-07

Similar Documents

Publication Publication Date Title
CY1114842T1 (el) Κιναζολινικα παραγωγα
CY1124617T1 (el) Ενωσεις βενζολιου υποκατεστημενες με αρυλιο ή ετεροαρυλιο
CY1112595T1 (el) Αμιδοφαινοξυινδαζολια χρησιμα ως αναστολεις του c-met
MA32938B1 (fr) Composes organiques
BRPI0908100A2 (pt) produto combinação, uso de um composto, e, método de tratar câncer
BR112017023821A2 (pt) moduladores de k-ras
CL2012002979A1 (es) Derivados de n3-sustituido-n1-sulfonil-5-fluorpirimidinona.
CY1120597T1 (el) Νεα χρηση
EA201300810A1 (ru) Противораковая терапия с использованием двойных ингибиторов киназ аврора/мек
BRPI0821118A2 (pt) método de completar um poço, método de tratar uma formação subterrânea interceptada por um poço, e método
ES2556353T8 (es) Compuestos que son inhibidores de las ERK
BRPI0914784A2 (pt) processamento de hidrocarbonetos usando radiação
DOP2014000033A (es) Aminoquinazolinas como inhibidores de quinasa
GT201300238A (es) Imidazopiridazinas como inhibidores de quinasa akt
CO6310993A2 (es) Moleculas utiles para el control de insectos
BR112013014566A2 (pt) fonte de evaporação linear, câmara de evaporação e método para revestir substratos
CY1117222T1 (el) Παραγωγα διαλκοξυκιναζολινης ως kdr αναστολεις
DK2452189T3 (da) Fremgangsmåde til identifikation af forbindelser til behandling af cancer
BRPI0709769B8 (pt) implantes biodegradáveis para o tratamento de estados associados à dopamina
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
IL213398A0 (en) Compounds for treating cancer
BRPI0909016A2 (pt) anticorpos úteis para o tratamento do câncer
BR112013029484A2 (pt) método para o tratamento de tumores sólidos avançados
BRPI0918508A2 (pt) orto-aminoanilidas para o tratamento de câncer
BRPI0918407A2 (pt) compostos organoarsênicos e métodos para o tratamento de câncer